TCF.LSE Theracryf Plc
- Market cap
- GBX 3.65M
- P/E
- -
- P/B
- 1.34x
- ROE
- -130.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is TCF.LSE undervalued?
Graham numberThe Graham number of Theracryf Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Theracryf Plc fundamental analysis
No fundamental analysis for Theracryf Plc yet.
Theracryf Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Theracryf Plc
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of cancers, neurodevelopmental disorders, and other diseases. The company was formerly known as Evgen Pharma plc and changed it…
Full company profileTheracryf Plc financial statements
Theracryf Plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | - | 194K | 0.00 | 442K | 396K | 0.00 | 0.00 |
| Gross Profit | -17.0K | -21.0K | -21.0K | -21.0K | -3.20M | -16.0K | 429K | 385K | -2.11M | -16.0K |
| Operating Income | -3.64M | -3.03M | -3.12M | -3.15M | -3.20M | -3.19M | -5.07M | -3.56M | -2.12M | -3.69M |
| EBITDA | -3.63M | -3.01M | -3.10M | -3.15M | -3.20M | -3.15M | -4.99M | -3.55M | -2.06M | -3.67M |
| Net Income | -3.07M | -2.58M | -2.62M | -2.72M | -2.67M | -2.73M | -4.04M | -3.14M | -1.94M | -3.53M |
| EPS | -0.04 | -0.03 | -0.03 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 4.74M | 4.26M | 2.76M | 4.86M | 12.4M | 9.64M | 6.17M | 3.06M | 7.63M | 4.81M |
| Total Liabilities | 514K | 389K | 688K | 653K | 607K | 411K | 833K | 721K | 1.66M | 2.10M |
| Shareholders' Equity | 4.23M | 3.87M | 2.08M | 4.20M | 11.8M | 9.23M | 5.34M | 2.34M | 5.97M | 2.72M |
| Cash & Short-term Investments | 3.86M | 3.63M | 2.03M | 4.13M | 11.6M | 9.03M | 5.00M | 2.00M | 4.11M | 1.54M |
| Total Debt | - | - | - | - | - | - | - | - | - | 11.0K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.19M | -2.34M | -2.29M | -2.58M | -2.93M | -2.56M | -4.03M | -3.00M | -2.37M | -2.55M |
| Capital Expenditure | 76.0K | 7.00K | 0.00 | 1.00K | 5.00K | 3.00K | 1.00K | 0.00 | 0.00 | 17.0K |
| Free Cash Flow | -3.27M | -2.35M | -2.29M | -2.58M | -2.93M | -2.56M | -4.03M | -3.00M | -2.37M | -2.56M |
| Ratios | ||||||||||
| ROE | -72.6% | -66.7% | -126.4% | -64.6% | -22.6% | -29.6% | -75.7% | -134.0% | -32.5% | -130.0% |
| ROA | -64.7% | -60.6% | -94.9% | -55.9% | -21.5% | -28.3% | -65.5% | -102.4% | -25.4% | -73.3% |
| Net Profit Margin | - | - | - | - | -1,378.4% | - | -914.7% | -792.2% | - | - |
| Debt to Equity | - | - | - | - | - | - | - | - | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Theracryf Plc dividends
Theracryf Plc has not paid dividends in the last 10 fiscal years.
Last stock split: 1027:1012 on Feb 12, 2021.
Who owns Theracryf Plc
- Insiders 49.66%
- Institutions 26.13%
- Public & others 24.21%
- Shares outstanding 2.15B
- Free float 1.42B
Theracryf Plc company profile
- Company name
- Theracryf Plc
- Ticker
- TCF.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- March
- Address
- Alderley Park, Nether Alderley, United Kingdom, SK10 4TG
- Phone
- 44 1625 315 090
- Website
- theracryf.com
About Theracryf Plc
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of cancers, neurodevelopmental disorders, and other diseases. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Theracryf Plc management
4- Dr. Huw Jones BSc, Ph.D.CEO & Executive Director · born 1959
- Mr. Toni Markus Antero HaenninenCFO & Director · born 1977
- Dr. Helen Kuhlman Ph.D.Chief Operating Officer
- Dr. Glen Clack FFPM, M.D.Chief Medical Officer